International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Trial Profile

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Epratuzumab (Primary) ; Asparaginase; Asparaginase; Crisantaspase; Crisantaspase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Prednisolone; Tioguanine; Vincristine; Vindesine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 May 2018 Planned End Date changed from 1 Jul 2023 to 1 Nov 2023.
    • 30 May 2018 Planned primary completion date changed from 1 Dec 2022 to 1 May 2023.
    • 22 Mar 2018 Planned End Date changed from 1 Jul 2021 to 1 Jul 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top